{"id":"glatiramer-acetate-ol","safety":{"commonSideEffects":[{"rate":"~90%","effect":"Injection site reactions (erythema, induration, pruritus)"},{"rate":"~10-15%","effect":"Immediate post-injection reaction (flushing, chest tightness, dyspnea, palpitations)"},{"rate":"~5-10%","effect":"Lipoatrophy at injection sites"},{"rate":"~10%","effect":"Headache"},{"rate":"~5%","effect":"Arthralgia"},{"rate":"~5%","effect":"Infection (upper respiratory)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glatiramer acetate mimics myelin basic protein and acts as a decoy antigen, shifting the immune response from pro-inflammatory Th1 cells toward anti-inflammatory Th2 and regulatory T cells. This reduces autoreactive T cell attack on myelin in the central nervous system. The drug also promotes the expansion of myelin-reactive regulatory T cells that suppress pathogenic immune responses.","oneSentence":"Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell responses against myelin antigens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:01.628Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (RRMS)"},{"name":"Clinically isolated syndrome (CIS) with high risk of MS"}]},"trialDetails":[{"nctId":"NCT00666224","phase":"PHASE3","title":"Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-01","conditions":"Multiple Sclerosis","enrollment":481}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Copaxone®"],"phase":"phase_3","status":"active","brandName":"Glatiramer Acetate (OL)","genericName":"Glatiramer Acetate (OL)","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell responses against myelin antigens. Used for Relapsing-remitting multiple sclerosis (RRMS), Clinically isolated syndrome (CIS) with high risk of MS.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}